- $1.09bn
- $693.87m
- £20.08m
- 23
- 10
- 54
- 19
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.75 | ||
| Price to Tang. Book | 3.05 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 46.31 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -37.97% | ||
| Return on Equity | -33.23% | ||
| Operating Margin | -802.76% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 9.11 | 9.67 | 27.36 | 27.22 | 20.08 | 48.12 | 31.57 | 21.85% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Exscientia PLC is a United Kingdom-based artificial intelligence (AI)-driven precision medicine company. It is focused on discovering, designing, and developing the possible drugs. It has developed the functional precision oncology platform to guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Its internal pipeline is focused on leveraging its precision medicine platform in oncology, while its partnered pipeline broadens its approach to other therapeutic areas. Its patient-first AI platform includes Patient-first AI, Precision Target, Precision Design, Precision Experiment, and Precision Medicine. Its Precision Target combines genetic data and global literature in machine learning models to anticipate and confirm disease-target associations. The Company’s advanced biophysical and x-ray techniques provide the ideal experimental underpinnings for AI-design.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- June 29th, 2021
- Public Since
- October 1st, 2021
- No. of Employees
- 483
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 213,011,627
- Address
- The Schrodinger Building, OXFORD, OX4 4GE
- Web
- https://www.exscientia.ai/
- Phone
- +44 1865818941
- Contact
- Sara Sherman
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for EXAI
Q3 2024 Exscientia PLC Earnings Release
Similar to EXAI
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Exscientia share price?
As of Today at 20:37 UTC, shares in Exscientia are trading at $5.39. This share price information is delayed by 15 minutes.
How has the Exscientia share price performed this year?
Shares in Exscientia last closed at $5.39 and the price had moved by -19.31% over the past 365 days. In terms of relative price strength the Exscientia share price has underperformed the S&P500 Index by -35.79% over the past year.
What are the analyst and broker recommendations for Exscientia?
The overall consensus recommendation for Exscientia is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Exscientia dividend yield?
Exscientia does not currently pay a dividend.
Does Exscientia pay a dividend?
Exscientia does not currently pay a dividend.
When does Exscientia next pay dividends?
Exscientia does not currently pay a dividend.
How do I buy Exscientia shares?
To buy shares in Exscientia you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Exscientia?
As of the previous close price of $5.39, shares in Exscientia had a market capitalisation of $1.15bn.
Where are Exscientia shares listed?
Here are the trading details for Exscientia:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: EXAI
What kind of share is Exscientia?
Based on an overall assessment of its quality, value and momentum Exscientia is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Exscientia share price forecast for 2024?
The analyst consensus target price for shares in Exscientia is $8.33. That is 54.55% above the last closing price of $5.39.
Analysts covering Exscientia currently have a consensus Earnings Per Share (EPS) forecast of -£0.84 for the next financial year.
What is the trend in the Exscientia share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Exscientia. Over the past six months, its share price has underperformed the S&P500 Index by -28.32%.
As of the last closing price of $5.39, shares in Exscientia were trading -3.09% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Exscientia PE Ratio?
The Exscientia PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $5.39.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Exscientia?
We do not have data on Exscientia's directors